[6-K] Concord Medical Services Holding Limited Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Concord Medical Services Holdings Ltd. (NYSE: CCM) has filed a Form 6-K to disclose that its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. (HKSE: 2453.HK), signed a placing agreement on 22 July 2025 with Guotai Junan Securities (Hong Kong). Under the agreement the placing agent will, on a best-effort basis, place 48,723,600 new H-shares with at least six independent investors at HK$5.54 per share. The issuance will be made under Concord Healthcare’s existing general mandate. No financial statements, earnings figures or projected proceeds were provided in the filing.

The transaction increases Concord Healthcare’s share count and is intended to raise fresh capital for the subsidiary; however, the filing does not state the specific use of proceeds or anticipated dilution for Concord Medical’s shareholders. The parent reiterates that additional details on the subsidiary’s Hong Kong transactions can be found on the HKEX website.

Insights

Equity Capital Markets Analyst

TL;DR: Subsidiary share placing raises capital; modest positive, dilution risk limited to H-share base.

The placing adds liquidity and capital to Concord Healthcare without leveraging the parent balance sheet, which is generally beneficial for growth funding. Pricing at HK$5.54 suggests market-aligned valuation, reducing placement discount concerns. Because the issue is under the subsidiary’s general mandate, execution risk is minimal. For U.S.-listed CCM holders, economic impact depends on Concord Medical’s ownership percentage; the filing does not disclose dilution at the parent level, keeping near-term valuation impact neutral. Overall, the event is operationally positive but financially immaterial until usage of proceeds is specified.

Corporate Governance Expert

TL;DR: Routine capital raise; governance sound, disclosure sparse.

The company follows established HKSE procedures, using an independent placing agent and pursuing at least six third-party placees, which supports fair allocation and mitigates related-party risk. Filing on Form 6-K satisfies U.S. disclosure obligations. However, lack of detail on proceeds utilisation and dilution metrics limits transparency. Investors should monitor future filings for capital deployment efficiency.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-34563

CONCORD MEDICAL SERVICES HOLDINGS LIMITED

Room A1-A5 26/F, East Zone, Hanwei Plaza

No. 7 Guanghua Road, Chaoyang District,

Beijing 100020

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F          x                 Form 40-F          ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Concord Healthcare Announces Placing of New Shares Pursuant to the Placing Agreement under General Mandate

Concord Healthcare Group Co., Ltd. (“Concord Healthcare”), a subsidiary of Concord Medical Services Holdings Limited (the “Company”) (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “HKSE”) under the stock code 2453.HK, announced that Concord Healthcare entered into a placing agreement with Guotai Junan Securities (Hong Kong) Limited (the “Placing Agent”) on July 22, 2025. Pursuant to the placing agreement, the Placing Agent has conditionally agreed to act as Concord Healthcare’s sole placing agent and to procure, on a best effort basis, not less than six (6) placees, who and whose ultimate beneficial owner(s) (where applicable) shall be independent third parties, to subscribe for 48,723,600 placing shares at the placing price of HK$5.54 per placing share (together with such brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee to the extent payable by the placees).

The Company previously announced the listing of Concord Healthcare’s H shares on the HKSE on January 9, 2024. The information related to Concord Healthcare’s Transactions on the HKSE is accessible through the HKSE’s website at www.hkexnews.hk.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CONCORD MEDICAL SERVICES HOLDINGS LIMITED
	By:	/s/ Jianyu Yang
	Name:	Jianyu Yang
	Title:	Chairman and Chief Executive Officer

Date: July 22, 2025